Bryer E, Mintzer D, Henry D: 2018 at a glance: recently approved therapies in oncology MD Edge/Hematology and Oncology : ://mdedge-files-live.s3.us-east-2.amazonaws.com,2019.
Deshields TL, Dueck AC, Rogers K, Brown JR, Shanafelt T, Mintzer D, Byrd JC: Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance). Leukemia and Lymphoma : 1-4,2019.
Bryer E, Neault M, Mintzer D: Managing Dying: Medical Care and Decision Making at the Very End of Life Palliative Medicine and Care: Open Access : 2019.
Mintzer D: MKSAP Oncology, Sections on melanoma, lymphoma, survivorship/complications of chemotherapy ACP 17 : 2018.
Mintzer DM: 2017 Notches Up Some Landmark Approvals Journal of Community and Supportive Oncology 15 (6): e346,2017.
Granda-Cameron C, Behta M, Hovinga M, Rundio A, Mintzer D.: Risk factors associated with unplanned hospital readmissions in adults with cancer. Oncol Nurs Forum 42 (3): E257-68,2015.
Mintzer D: Generalizations of a generalist Journal of Community and Supportive Oncology in press : 2015.
Raess Philipp W, Mintzer David, Husson Michael, Nakashima Megan O, Morrissette Jennifer J D, Daber Robert, Bagg Adam: BRAF V600E is also seen in unclassifiable splenic B-cell lymphoma/leukemia, a potential mimic of hairy cell leukemia. Blood 122 (17): 3084-5,2013.
Mintzer David M: Oncodoxes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31 (3): 393-4,2013.
Dotan Efrat, Meropol Neal J, Burtness Barbara, Denlinger Crystal S, Lee James, Mintzer David, Zhu Fang, Ruth Karen, Tuttle Holly, Sylvester Judi, Cohen Steven J: A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. Journal of gastrointestinal cancer 43 (4): 562-9,2012.